title: [Pulmonary manifestations of inflammatory bowel disease].
abstract: Pulmonary disease is a rare complication of inflammatory bowel disease. Airway inflammation, interstitial lung disease and several other manifestations have been described, and typical symptoms are productive cough, chest pain, and progressive dyspnea. Due to the frequency of preceding pulmonary disease and the common temporal dissociation regarding intestinal disease, pulmonary manifestations of inflammatory bowel disease are at high risk of being overlooked. If suspected, early work-up including CT scan and bronchoscopy should be initiated, since the natural course often involves rapidly progressive lung damage. The best therapeutic results have been obtained with topic and systemic steroids, while classic immunosuppressants are commonly not efficacious. Several case reports describe a beneficial effect of infliximab.
authors.affiliation: Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625, Hannover, Deutschland. bachmann.oliver@mh-hannover.de
authors.forename: O
authors.initials: O
authors.lastname: Bachmann
authors.forename: F
authors.initials: F
authors.lastname: Länger
authors.forename: J
authors.initials: J
authors.lastname: Rademacher
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001999:Bronchoscopy; D002637:Chest Pain / Q000209:etiology; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000188:drug therapy; D003371:Cough / Q000209:etiology; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy; D004417:Dyspnea / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008171:Lung Diseases / Q000175:diagnosis* / Q000188:drug therapy; D019804:Mesalamine / Q000009:adverse effects / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D019804:Mesalamine; D000069285:Infliximab